These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 35356200)
1. Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity. Wu Y; Lin H; You X; Guo T; Sun T; Xu H; Fu X Front Oncol; 2022; 12():764923. PubMed ID: 35356200 [TBL] [Abstract][Full Text] [Related]
2. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. Pinter M; Jain RK; Duda DG JAMA Oncol; 2021 Jan; 7(1):113-123. PubMed ID: 33090190 [TBL] [Abstract][Full Text] [Related]
3. Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis. Liu H; Yang CC; Ma YL; Yang YF; Yan LJ; Ding ZN; Xue JS; Yang LS; Yan YC; Dong ZR; Wang DX; Chen ZQ; Hong JG; Li T Immunotherapy; 2023 Jun; 15(9):669-678. PubMed ID: 37140011 [TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Liu X; Qin S Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Pinter M; Scheiner B; Peck-Radosavljevic M Gut; 2021 Jan; 70(1):204-214. PubMed ID: 32747413 [TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725 [TBL] [Abstract][Full Text] [Related]
7. The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. Ozer M; George A; Goksu SY; George TJ; Sahin I Front Oncol; 2021; 11():801379. PubMed ID: 34956912 [TBL] [Abstract][Full Text] [Related]
8. Does immune checkpoint inhibitor exhibit limited efficacy against non-viral hepatocellular carcinoma?: A review of clinical trials. Eso Y; Taura K; Seno H Hepatol Res; 2022 Jan; 52(1):67-74. PubMed ID: 34520619 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. Plaz Torres MC; Lai Q; Piscaglia F; Caturelli E; Cabibbo G; Biasini E; Pelizzaro F; Marra F; Trevisani F; Giannini EG J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34361985 [TBL] [Abstract][Full Text] [Related]
10. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
11. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. D'Alessio A; Rimassa L; Cortellini A; Pinato DJ J Hepatocell Carcinoma; 2021; 8():887-897. PubMed ID: 34386437 [TBL] [Abstract][Full Text] [Related]
12. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. Luo XY; Wu KM; He XX J Exp Clin Cancer Res; 2021 May; 40(1):172. PubMed ID: 34006331 [TBL] [Abstract][Full Text] [Related]
14. Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma. Wang T; Zhang Q; Wang N; Liu Z; Zhang B; Zhao Y Curr Med Chem; 2021; 28(16):3107-3146. PubMed ID: 33050856 [TBL] [Abstract][Full Text] [Related]
15. Identification of a Ferroptosis-Related Long Noncoding RNA Prognostic Signature and Its Predictive Ability to Immunotherapy in Hepatocellular Carcinoma. Wang L; Ge X; Zhang Z; Ye Y; Zhou Z; Li M; Yan H; Wu L; Bai Q; Li J; Zhu J; Wang Y Front Genet; 2021; 12():682082. PubMed ID: 34745200 [No Abstract] [Full Text] [Related]
16. Trans-arterial chemoembolization combined with Jinlong capsule for advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis in a Chinese population. Jia S; Fu Y; Tao H Pharm Biol; 2020 Dec; 58(1):771-784. PubMed ID: 32767901 [TBL] [Abstract][Full Text] [Related]